Symbiosis Recognised by EcoVadis for Sustainability Commitment.

Stirling, UK – 31 March 2025 – Symbiosis Pharmaceutical Services, a prominent Contract Manufacturing Organisation (CMO) specialising in sterile Good Manufacturing Practice (GMP) biopharmaceutical production, has received notable recognition from EcoVadis, a globally trusted authority on corporate sustainability ratings.

The company has been awarded the EcoVadis Committed Badge for its progress in carbon emissions reduction and alignment with the Science Based Targets initiative (SBTi), marking a significant step in its journey toward environmental stewardship.

This accolade reinforces Symbiosis’ dedication to incorporating environmental, social, and governance (ESG) practices throughout its business model and supply chain. By embedding sustainability into its core operations, the company demonstrates a forward-thinking approach to responsible manufacturing in the pharmaceutical industry.

As part of its comprehensive sustainability roadmap, Symbiosis has completed a carbon footprint assessment and established measurable goals for emissions reduction. Several major environmental initiatives are already underway. These include powering its operations entirely with renewable electricity, installing heat recovery systems, and integrating air source heat pumps to support HVAC systems — all aimed at enhancing overall energy efficiency.

The company is also implementing water-saving measures through advanced recirculation processes. These initiatives collectively are expected to cut carbon dioxide emissions by 151.7 tonnes. A key milestone in the plan is the transition to 100% renewable energy in 2025, projected to reduce emissions by 37%.

Colin MacKay, CEO of Symbiosis, emphasised the strategic importance of sustainability in the company’s development plans. “As we continue to expand our world-class sterile manufacturing operations, sustainability remains a central pillar of our growth strategy,” said MacKay. “This recognition from EcoVadis affirms our practical commitment to reducing our environmental footprint. Symbiosis is proud to contribute to a greener, more sustainable biopharmaceutical sector.”

With increasing demand for its sterile fill/finish capabilities, Symbiosis remains focused on delivering high-quality, GMP-compliant solutions while maintaining environmental responsibility.

The company, based in Stirling, recently completed a successful FDA inspection of its facilities and quality systems. In support of its growing client base, Symbiosis has also expanded its operations with the completion of a new, state-of-the-art automated sterile GMP manufacturing facility adjacent to its existing site. This development significantly boosts its capacity to serve pharmaceutical and biotech companies throughout the clinical and commercial drug development lifecycle.

About Symbiosis Pharmaceutical Services:

Symbiosis, headquartered in Stirling, Scotland, is a specialist CMO focused on sterile GMP manufacturing of biologics and small molecule drugs for clinical trials and global commercial markets. The MHRA-licensed and FDA-inspected facility provides aseptic fill/finish services, analytical testing, Qualified Person (QP) release, labelling, packaging, and GMP-compliant storage and shipment.

The company’s strength lies in its regulatory compliance, technical expertise, and agile operations — all delivered by a team of seasoned life sciences professionals. Symbiosis supports rapid, high-quality production for time-sensitive clinical programs and commercial launches.

About EcoVadis:

EcoVadis is a global leader in sustainability assessments, evaluating companies based on environmental, ethical, and social respond.

Source:https://www.bioitworld.com/pressreleases/2025/04/22/symbiosis-earns-recognition-from-ecovadis-for-commitment-to-sustainability

This is non-financial/medical advice and made using AI so could be wrong.